What is ASTC's 12-month stock price target?

Astrotech Corporation (ASTC) carries a 12-month consensus base price target of $4.19 (-13.4% from $4.84), with a bull-case target of $72.29 and a bear-case floor of $3.27.

Stock Ratings / Health Care / ASTC / forecast

BNGO (29) EYPT (26) PRPO (30) RPID (34) ⌘ Pro Terminal →

Astrotech Corporation (ASTC) 12-Month Stock Forecast & Price Target Cone

Q: Is ASTC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ASTC E (Strong Sell — SELL) with an RQD Confidence score of 28/100.

$4.84 -7.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.76

Astrotech Corporation (ASTC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $10.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ASTC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ASTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.84 (-7.81% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ASTC ranks #873 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ASTC compare to BNGO and EYPT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ASTC?

▼

Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.76 (-1.60%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASTC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY ASTC SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$6.06-19.6% Next Q

Q2 (-2Q)

Grade E$4.87+7.4% Next Q

Q3 (-1Q)

Grade E$5.23-7.5% Next Q

Current

Grade E$4.84-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ASTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ASTC currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.40) and Max Pain ($5.08) forces dealer call-delta covering toward $72.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ASTC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ASTC Position Size: $10,000

Shares at $4.84: 2066.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.27

$6,756

$-3,244 (-32.4%)

12M Consensus BaseTarget $4.19

$8,657

$-1,343 (-13.4%)

12M Bull Case BreakoutTarget $72.29

$149,360

+$139,360 (+1393.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$68	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASTC)

✓Walkthrough of ASTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ASTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +67.47%⚡ TESTING RESISTANCE

2026-11-03O $5.25H $5.25L $4.84C $4.84VOL 17.9K

RES: $4.93SUP: $4.04SMA50: $6.40SMA200: $7.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASTC Butterfly Map → + Track ASTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -41.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ASTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ASTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASTC)

Health Care Rank #873 of 1016 ⚔️ BNGO vs ASTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASTC vs. BNGO, EYPT, PRPO, RPID)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Astrotech Corporation (ASTC) ranks #873 by composite RQD confidence (28/100, grade E) and #890 by equity capitalization ($10.2M). Within this direct 5-issuer industry benchmark cohort, ASTC leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with ASTC at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ASTC ACTIVE Astrotech Corporation	E	28/100	—	47.5%	-35.0%	-7.81%	$10.2M	Benchmark Subject
BNGO Bionano Genomics Inc.	E	29/100	—	46.3%	-35.0%	-4.17%	$16.1M	/bngo-vs-astc →
EYPT EyePoint Inc.	E	26/100	—	—	-35.0%	-8.32%	$30.0M	/eypt-vs-astc →
PRPO Precipio Inc.	E	30/100	—	44.2%	-7.9%	-6.46%	$32.4M	/prpo-vs-astc →
RPID Rapid Micro Biosystems Inc. (Class A)	E	34/100	—	—	-35.0%	-6.73%	$36.9M	/rpid-vs-astc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001001907

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Astrotech Corporation (ASTC) reported GAAP revenue of $1.0M (-41.2% vs. FY2024 revenue of $1.7M , and +33.3% cumulative change since FY2023) , GAAP net income of -$13.8M, operating cash flow of -$13.0M, and free cash flow of -$13.8M (-33.8% YoY). On the balance sheet, ASTC closed FY2025 with $19.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.0M	-$13.8M	-$13.0M	-$13.8M	$19.7M	—
FY2024 (FY)	2024-06-30	$1.7M	-$11.7M	-$9.7M	-$10.3M	$31.0M	—
FY2023 (FY)	2023-06-30	$750.0K	-$9.6M	-$7.6M	-$7.6M	—	—

3. ASTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ASTC compare to BNGO and EYPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ASTC?

Where is ASTC trading relative to its 50-day, 200-day, and 52-week technical levels?

ASTC last traded at $4.84 (-7.81% on volume of 17,874 shares), positioning the stock -24.38% below its 50-day simple moving average ($6.40) and -32.96% below its 200-day simple moving average ($7.22). Across its 52-week range of $1.92 to $68.85, ASTC sits at the 4.4% percentile with a 14-day RSI of 35.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.24 to $5.44).

Direct Sub-Reports: ASTC RQD Cockpit ASTC 12M Forecast ASTC Earnings & Move ASTC Dividends & DRIP ASTC Insiders & 13F ASTC Whale Options ASTC Profit Sankey ASTC News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ASTC — Astrotech Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:34Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ASTC carries an RQD Score of 28 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 3/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the two that measure whether the business generates value and whether informed capital is building positions. The cash engine pillar reflects a negative return on invested capital and a 0% free cash flow yield, meaning the reported financials do not currently show a self-funding operation. The flow pillars indicate little evidence of supportive institutional or insider conviction in the source data. The balance-sheet pillar is middling rather than distressed: the Altman Z-Score of 2.5 and Debt/Equity of 0.5 sit in the range the rating treats as neutral, but a Piotroski F-Score of 3 out of 9 points to weak financial-quality signals. Beta of 1.0 places macro sensitivity at market-average, so the rating's macro pillar does not add a directional penalty beyond sector exposure.

Upside drivers implied by the data would have to come from a turnaround in operating performance, which the reported trend does not yet show.1M market capitalization against negative operating and net margins. The 52-week range of $1.92 - $68.85 is extremely wide and should be weighed as evidence of volatility rather than as a valuation anchor.

Business

Astrotech Corporation (ASTC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Gross margin is reported at 47.5%, while operating and net margins are both reported at -60%. —

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the most recent headline reports an Astrotech proposal to provide lunar power infrastructure under a NASA program, flagged YELLOW. A second headline states that at least $20M in sale value is needed for first bonuses under a new plan, flagged YELLOW. A Form 4 filing by director Tom Wilkinson is listed, flagged YELLOW. A "Risk Watch" item titled "Discipline and Rules-Based Execution in ASTC Response" is flagged RED. A price-action item reports the stock slipping 1.92% to $5.10, and a Manila Times item references an appointment of a Chief Financial Officer at Innventure, a separate entity, which the source does not connect to ASTC operationally. The proprietary signals list in the Butterfly graph is empty.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The only sector-level context provided is the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry classification. A prospective investor should watch whether the NASA-related lunar infrastructure proposal translates into revenue, since the source does not establish any link between that activity and the reported health-care industry classification.

Open Questions

What drives the reported revenue increase in FY 2024 and subsequent decline in FY 2025, and what products or services generate it?
What are the cash and debt balances, since both are listed as N/A across all reported periods?
What is the relationship between the NASA lunar power proposal and the company's reported health-care industry classification?
What is the status and size of the new bonus plan referenced in the news flow, and how does it affect dilution or cash burn?
Given the Beta of 1.0 and the wide 52-week range, what explains the extreme price volatility in the source period?

ASTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Astrotech Corporation (ASTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ASTC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

Astrotech Makes Proposal to Provide Advanced Lunar Power Infrastructure Under NASA NextSTEP-3 Program

Yahoo Finance report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

At least $20M in sale value is needed for 1st Detect bonuses under Astrotech (ASTC)'s new plan.

Stock Titan report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Nigeria • 1d ago

Form 4 Astrotech Corp: Tom Wilkinson (Director) For: 30 September By Investing.com

Investing.com Nigeria report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 1d ago

Discipline and Rules-Based Execution in ASTC Response

Stock Traders Daily report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Astrotech (ASTC) Slips 1.92% to $5.10, Testing the Lower Half of Its Recent Range - Fibonacci Fan

https://www.dars.gov.et/ report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

Innventure Welcomes Eric Stober as Chief Financial Officer

The Manila Times report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 14d ago

Astrotech Submits Proposal For The NASA Next Space Technologies For Exploration Partnerships-3 Lunar Enabling Infrastructure Accelerator Regarding Its Vertical Solar Array

The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 18d ago

12 Information Technology Stocks Moving In Thursday's Intraday Session

Gainers Republic Power Group (NASDAQ:RPGL) stock moved upwards by 55.5% to $24.09 during Thursday's regular session. The company's market cap stands at $44.9 million. Alpha Modus Holdings (NASDAQ:AMOD) shares

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ASTC Bull vs. Bear Conversation Board — What's Your Call at $4.84?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASTC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.62 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ASTC (E • RQD 28/100) a Buy at $5.25?

Welcome to the ASTC (Astrotech Corporation) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.41 (-16.0%)

Spot @ $5.25

Pump the brakes on ASTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ASTC, but look at what you are paying: current EV/EBITDA multiples with 47.5% gross margins. Unless Astrotech Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.51 (+24.0%)

Spot @ $5.25

ASTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ASTC, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $5.25 (52-wk range $1.92 - $68.85), any beat on forward guidance forces shorts and underweight funds to chase.